减肥圈爆火的“躺瘦神器"司美格鲁肽，你能用吗？

Core Viewpoint - Semaglutide, a GLP-1 receptor agonist developed by Novo Nordisk, has gained significant attention as a weight loss drug, achieving global sales exceeding $35 billion last year due to its dual effects of weight loss and blood sugar control [5]. Group 1: Weight Loss Effects - Clinical data indicates that patients using semaglutide for 68.1 weeks experienced an average weight loss of 15%, with a median weight reduction of 15.3 kg [6]. - A study published in The Lancet showed that patients receiving 2.4 mg of semaglutide weekly lost 12.1% of their body weight after 44 weeks, compared to a 3.6% loss in the placebo group [6]. - Long-term effects of semaglutide treatment can sustain weight loss for over 65 weeks, with an average weight loss of 10.2% and waist circumference reduction of 7.7 cm after 208 weeks [6]. Group 2: Safety Profile - Semaglutide is suitable for individuals with poorly controlled type 2 diabetes, those with comorbidities like coronary heart disease, and obese patients with at least one complication [8]. - Common side effects include gastrointestinal discomfort, such as nausea and diarrhea, which are generally mild to moderate and decrease over time [8]. - The FDA updated the safety label in August 2023, warning of potential increased risk of intestinal obstruction, and studies suggest possible risks for gallbladder disease and pancreatitis [8]. Group 3: Advantages Over Traditional Weight Loss Drugs - Semaglutide shows a weight loss effect of 11.41%, significantly higher than older drugs that typically achieve around 5% weight loss, with some banned drugs showing only 2-3% [9]. - Compared to liraglutide, which has a weight loss effect of 4.68%, semaglutide demonstrates superior efficacy [9]. Group 4: Comparison with Weight Loss Surgery - Semaglutide's efficacy is comparable to that of weight loss surgery, but it is considered safer and is recommended as the first-line option in weight loss guidelines [13]. Group 5: Administration Methods - Semaglutide is available in both injectable and oral forms, with the injectable version requiring weekly administration, while the oral form necessitates daily intake [16]. - The injectable form requires refrigeration, while the oral version can be stored at room temperature, providing more convenience for patients [18]. Group 6: Additional Benefits - Semaglutide is approved for use in patients with a BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with obesity-related complications, aiming to reduce risks of diabetes, hypertension, and cardiovascular diseases [19]. - In March 2024, the FDA approved a new indication for semaglutide to lower cardiovascular risks in obese or overweight adults with existing cardiovascular conditions [19].